$FTLF
FITLIFE BRANDS, INC.

2023 Q2 Form 10-Q Financial Statement

#000143774923014633 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $14.76M $10.74M $5.370M
YoY Change 84.52% 44.04% -22.16%
Cost Of Revenue $8.795M $6.330M $3.182M
YoY Change 102.93% 51.33% -20.21%
Gross Profit $5.965M $4.408M $2.188M
YoY Change 62.76% 34.72% -24.84%
Gross Profit Margin 40.41% 41.05% 40.74%
Selling, General & Admin $3.243M $2.344M $1.390M
YoY Change 77.89% 41.03% -10.9%
% of Gross Profit 54.37% 53.18% 63.53%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $13.00K $19.00K $17.00K
YoY Change 85.71% 35.71% -5.56%
% of Gross Profit 0.22% 0.43% 0.78%
Operating Expenses $3.381M $3.735M $1.407M
YoY Change 83.75% 122.85% -10.84%
Operating Profit $2.584M $673.0K $781.0K
YoY Change 41.59% -57.83% -41.41%
Interest Expense $251.0K $98.00K $62.00K
YoY Change 2688.89% 1300.0% 785.71%
% of Operating Profit 9.71% 14.56% 7.94%
Other Income/Expense, Net $15.00K -$96.00K
YoY Change 66.67% -1471.43%
Pretax Income $2.599M $577.0K $800.0K
YoY Change 41.71% -64.0% -40.3%
Income Tax $635.0K $421.0K $327.0K
% Of Pretax Income 24.43% 72.96% 40.88%
Net Earnings $1.964M $156.0K $473.0K
YoY Change 35.82% -87.91% -55.04%
Net Earnings / Revenue 13.31% 1.45% 8.81%
Basic Earnings Per Share $0.44 $0.03
Diluted Earnings Per Share $0.40 $0.03 $0.10
COMMON SHARES
Basic Shares Outstanding 4.446M 4.446M 4.556M
Diluted Shares Outstanding 4.887M 4.935M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.882M $7.977M $13.28M
YoY Change -27.81% -27.88% 34.15%
Cash & Equivalents $9.833M $8.927M $13.28M
Short-Term Investments
Other Short-Term Assets $1.520M $2.397M $116.0K
YoY Change 198.04% 1352.73% -60.68%
Inventory $9.148M $8.791M $9.105M
Prepaid Expenses
Receivables $1.575M $2.045M $705.0K
Other Receivables $1.322M $0.00 $0.00
Total Short-Term Assets $22.45M $21.21M $23.20M
YoY Change 5.46% 6.0% 31.41%
LONG-TERM ASSETS
Property, Plant & Equipment $162.0K $118.0K $46.00K
YoY Change 174.58% 100.0% -79.82%
Goodwill $13.56M $10.79M $358.0K
YoY Change 3687.43% 2913.13% 0.0%
Intangibles $7.957M $7.769M $150.0K
YoY Change 4553.22% 4192.27% -21.88%
Long-Term Investments
YoY Change
Other Assets $1.344M $1.596M $1.847M
YoY Change -42.86% -41.67% -39.34%
Total Long-Term Assets $23.19M $20.46M $2.504M
YoY Change 655.03% 486.94% -34.5%
TOTAL ASSETS
Total Short-Term Assets $22.45M $21.21M $23.20M
Total Long-Term Assets $23.19M $20.46M $2.504M
Total Assets $45.63M $41.67M $25.71M
YoY Change 87.37% 77.34% 19.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.571M $4.881M $2.995M
YoY Change 41.99% 43.1% 3.99%
Accrued Expenses $3.157M $1.987M $685.0K
YoY Change 288.31% 250.44% 18.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.500M $2.500M $0.00
YoY Change
Total Short-Term Liabilities $9.817M $9.949M $4.270M
YoY Change 147.65% 114.79% 4.38%
LONG-TERM LIABILITIES
Long-Term Debt $9.375M $10.00M $0.00
YoY Change
Other Long-Term Liabilities $85.00K $108.0K $49.00K
YoY Change 11.84% 20.0% -52.43%
Total Long-Term Liabilities $9.375M $10.00M $49.00K
YoY Change 12235.53% 11011.11% -52.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.817M $9.949M $4.270M
Total Long-Term Liabilities $9.375M $10.00M $49.00K
Total Liabilities $21.78M $20.06M $4.319M
YoY Change 439.21% 324.76% 2.98%
SHAREHOLDERS EQUITY
Retained Earnings -$6.593M -$8.557M -$8.713M
YoY Change -36.64% -27.8% -33.7%
Common Stock $44.00K $44.00K $45.00K
YoY Change -4.35% -4.35% -2.17%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change -100.0%
Treasury Stock Shares $0.00
Shareholders Equity $23.85M $21.61M $21.39M
YoY Change
Total Liabilities & Shareholders Equity $45.63M $41.67M $25.71M
YoY Change 87.37% 77.34% 19.68%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income $1.964M $156.0K $473.0K
YoY Change 35.82% -87.91% -55.04%
Depreciation, Depletion And Amortization $13.00K $19.00K $17.00K
YoY Change 85.71% 35.71% -5.56%
Cash From Operating Activities $1.562M $232.0K -$873.0K
YoY Change 25.56% -79.54% -168.2%
INVESTING ACTIVITIES
Capital Expenditures $54.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$17.10M $0.00
YoY Change
Cash From Investing Activities -$54.00K -$17.10M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities -625.0K $12.50M -779.0K
YoY Change 43003.45%
NET CHANGE
Cash From Operating Activities 1.562M $232.0K -873.0K
Cash From Investing Activities -54.00K -$17.10M 0.000
Cash From Financing Activities -625.0K $12.50M -779.0K
Net Change In Cash 883.0K -$4.350M -1.652M
YoY Change -29.02% -474.03% -229.06%
FREE CASH FLOW
Cash From Operating Activities $1.562M $232.0K -$873.0K
Capital Expenditures $54.00K $0.00
Free Cash Flow $1.508M $232.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
36000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
50000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
110000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
82000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
72000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4446000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4446000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4507000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4507000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
143000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-52369
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3464383
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5214 S. 136th Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Omaha
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NE
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
68137
CY2023Q1 dei City Area Code
CityAreaCode
402
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
991-5618
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4446161
CY2023Q1 us-gaap Cash
Cash
7977000 usd
CY2022Q4 us-gaap Cash
Cash
13277000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
950000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2045000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
705000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
8791000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9105000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1447000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
116000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
21210000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
23203000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
118000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7769000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
150000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
10787000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
358000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1596000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1847000 usd
CY2023Q1 us-gaap Assets
Assets
41665000 usd
CY2022Q4 us-gaap Assets
Assets
25707000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4881000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2995000 usd
CY2023Q1 ftlf Accrued Expense And Other Liabilities Current
AccruedExpenseAndOtherLiabilitiesCurrent
1897000 usd
CY2022Q4 ftlf Accrued Expense And Other Liabilities Current
AccruedExpenseAndOtherLiabilitiesCurrent
631000 usd
CY2023Q1 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
581000 usd
CY2022Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
590000 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
2500000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9949000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4270000 usd
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
10000000 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
108000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
20057000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4319000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
44000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
45000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30099000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30056000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8557000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8713000 usd
CY2023Q1 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
22000 usd
CY2022Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
0 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21608000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21388000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41665000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25707000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10738000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7294000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6330000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4183000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
4408000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
3111000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2344000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1495000 usd
CY2023Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
1372000 usd
CY2022Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
6000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3735000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1515000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
673000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1596000 usd
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
84000 usd
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
7000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
98000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
0 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-82000 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-0 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-96000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
577000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1603000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
421000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
313000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
156000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1290000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4483000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4554000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4935000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4980000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21388000 usd
CY2023Q1 ftlf Shares Surrendered By Former Employee
SharesSurrenderedByFormerEmployee
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
42000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
156000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21608000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17346000 usd
CY2022Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
-0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
107000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1290000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
18772000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
156000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1290000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000 usd
CY2023Q1 ftlf Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability
OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability
-16000 usd
CY2022Q1 ftlf Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability
OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability
-13000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-14000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
2000 usd
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
36000 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
42000 usd
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
107000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
917000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
741000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1501000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
611000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-251000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-309000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
44000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-157000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1045000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
532000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-16000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-13000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
290000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
22000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9000 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
22000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
232000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1134000 usd
CY2023Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
17099000 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
-0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17099000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12500000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12500000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4350000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1163000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13277000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9897000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8927000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11060000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE <em style="font: inherit;">1</em> - DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"); and (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “<i>MRC Products</i>"). The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.  The Company distributes the MRC Products primarily on Amazon.com.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s Common Stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the OTC Pink market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recent Developments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Acquisition of Mimi</i>’<i>s Rock Corp</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 4, 2022, </em>the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“<i>MRC</i>”), pursuant to which the Company agreed to acquire MRC. On <em style="font: inherit;"> February 28, 2023, </em>the Company completed the acquisition of MRC. See Note <em style="font: inherit;">8</em> for additional disclosure.</p> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Inflation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has experienced inflationary pressure with regard to the procurement of many of its products.  Thus far, the Company has been able to partially offset the impact of inflation through price increases to its customers.  In the future, however, further inflationary pressure could adversely affect the Company’s operating performance if market conditions <em style="font: inherit;">no</em> longer permit the Company to pass through price increases to its customers.</p>
CY2023Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE <em style="font: inherit;">2</em> - BASIS OF PRESENTATION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying interim condensed unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">8</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> March 31, 2023 </em>are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for the year ending <em style="font: inherit;"> December 31, 2023. </em>Although management of the Company believes the disclosures presented herein are adequate and <em style="font: inherit;">not</em> misleading, these interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the fiscal year ended <em style="font: inherit;"> December 31, 2022, </em>filed with the Securities and Exchange Commission (the “<i>SEC</i>”) on <em style="font: inherit;"> March 24, 2023.</em></p>
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, depreciable lives of property and equipment, purchase price allocations for business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p>
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
156000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1290000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4483000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4554000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
452000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
426000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4935000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4980000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Net sales to GNC during the <em style="font: inherit;">three</em>-month periods ended <em style="font: inherit;"> March 31, 2023 </em>and <em style="font: inherit;">2022</em> represent 49% and 70% of total net revenue, respectively. Gross accounts receivable attributable to GNC as of <em style="font: inherit;"> March 31, 2023 </em>and <em style="font: inherit;">2022</em> represent 32% and 82% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:34pt;"> </p>
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.730 pure
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195 pure
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
110000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7972000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8347000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
929000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
865000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
110000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
8791000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9105000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
897000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
902000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
779000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
856000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
118000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
19000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
14000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2500000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
12500000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1875000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2500000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2500000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2500000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2500000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
625000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
12500000 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000.0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4446000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4507000
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2023Q1 ftlf Shares Forfeited During Period Shares
SharesForfeitedDuringPeriodShares
61200000
CY2023Q1 ftlf Shares Forfeited During Period Value
SharesForfeitedDuringPeriodValue
0 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
379000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
379000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y1M6D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
379000
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y1M6D
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.09
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
340000
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.63
CY2023Q1 us-gaap Share Price
SharePrice
16.75
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5231000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
143000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
143000
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2238000 usd
CY2023Q1 ftlf Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2023Q1 ftlf Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
0
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.15
CY2023Q1 us-gaap Reclassifications
Reclassifications
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE <em style="font: inherit;">10</em> – RECLASSIFICATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Certain prior year amounts have been reclassified to conform to current presentation.  These reclassifications had <em style="font: inherit;">no</em> effect on the reported operating income or net income on the Condensed Consolidated Statement of Operations.  Certain expenses previously classified as selling, general and administrative expenses have been reclassified to a contra-revenue account on the Condensed Consolidated Statement of Operations.</p>

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001437749-23-014633-index-headers.html Edgar Link pending
0001437749-23-014633-index.html Edgar Link pending
0001437749-23-014633.txt Edgar Link pending
0001437749-23-014633-xbrl.zip Edgar Link pending
ex_517361.htm Edgar Link pending
ex_517362.htm Edgar Link pending
ex_517363.htm Edgar Link pending
ex_517364.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ftlf-20230331.xsd Edgar Link pending
ftlf20230331_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
ftlf-20230331_cal.xml Edgar Link unprocessable
ftlf-20230331_def.xml Edgar Link unprocessable
ftlf-20230331_lab.xml Edgar Link unprocessable
ftlf-20230331_pre.xml Edgar Link unprocessable
ftlf20230331_10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending